Restoring immune tolerance in neuromyelitis optica Part II

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 5, 2016, Pages

  Bar Or, Amit ^a   Steinman, Larry ^b   Behne, Jacinta M ^c   Benitez Ribas, Daniel ^d   Chin, Peter S ^e   Clare Salzler, Michael ^f   Healey, Donald ^g   Kim, James I ^h   Kranz, David M ⁱ   Lutterotti, Andreas ^j   Martin, Roland ^j   Schippling, Sven ^j   Villoslada, Pablo ^d   Wei, Cheng Hong ^o   Weiner, Howard L ^h   Zamvil, Scott S ^k   Smith, Terry J ^l   Yeaman, Michael R ^m,n  

^a MCGILL UNIVERSITY   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Guthy Jackson Charitable Foundation   (United States)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e GENENTECH INC   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g Opexa Therapeutics Inc   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ HARBOR UCLA MEDICAL CENTER   (United States)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85086440130     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000277     Document Type: Article

References (59)

1. Levy M, Wildemann B, Jarius S, et al. Immunopathogenesis of neuromyelitis optica. Adv Immunol 2014;121: 213–242.
2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473–477.
3. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1–16.
4. Sakaguchi S, Setoguchi R, Yang H, Nomura T. Naturally arising Foxp3-expressing CD251CD41 regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immunol 2006;305:51–66.
5. Shevach EM. CD41 CD251 suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389–400.
6. Thornton AM, Shevach EM. CD41CD251 immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287–296.
7. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD41CD25 high regulatory cells in human peripheral blood. J Immunol 2001;167:1245–1253.
8. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 2005;22:329–341.
9. Kim JM, Rudensky AY. The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev 2006;212:86–98.
10. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007;445:771–775.
11. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007;8:277–284.
12. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68–73.
13. Lahl K, Loddenkemper C, Drouin C, et al. Selective depletion of Foxp31 regulatory T cells induces a scurfy-like disease. J Exp Med 2007;204:57–63.
14. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007;8:191–197.
15. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006;24:209–226.
16. Buckner JH. Mechanisms of impaired regulation by CD4(1)CD25(1)FOXP3(1) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10:849–859.
17. Shevach EM. Mechanisms of foxp31 T regulatory cell-mediated suppression. Immunity 2009;30:636–645.
18. Fields ML, Seo SJ, Nish SA, Tsai JH, Caton AJ, Erikson J. The regulation and activation potential of autoreactive B cells. Immunol Res 2003;27:219–234.
19. Fields ML, Hondowicz BD, Wharton GN, et al. The regulation and activation of lupus-associated B cells. Immunol Rev 2005;204:165–183.
20. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523–532.
21. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD251 CD41 T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004;199:1467–1477.
22. Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting edge: CD41CD251 regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002;169: 4712–4716.
23. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L1 subpopulation of CD41CD251 regulatory T cells protects from lethal acute GVHD. Blood 2005;105: 2220–2226.
24. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117:3921–3928.
25. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(1)CD25(high) CD127-regulatory T cells prolongs survival of pancreatic islets: results of one year follow-up. Clin Immunol 2014; 153:23–30.
26. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004;199:1455–1465.
27. Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 2005;54:306–310.
28. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011;3:83ra42.
29. Kim YC, Zhang AH, Su Y, et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood 2015;125: 1107–1115.
30. Jiang S, Camara N, Lombardi G, Lechler RI. Induction of allopeptide-specific human CD41CD251 regulatory T cells ex vivo. Blood 2003;102:2180–2186.
31. Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther 2014;22:1018–1028.
32. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 2013;13: 3010–3020.
33. Bouaziz JD, Yanaba K, Venturi GM, et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD41 T cell activation in mice. Proc Natl Acad Sci USA 2007;104: 20878–20883.
34. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD41 T cells to protein antigens in vivo. J Immunol 1995;155:3734–3741.
35. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475–482.
36. Linton PJ, Bautista B, Biederman E, et al. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med 2003;197:875–883.
37. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012;209: 1001–1010.
38. Molnarfi N, Schulze-Topphoff U, Weber MS. MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013;210:2921–2937.
39. Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 2015;7:310ra166.
40. Carter NA, Vasconcellos R, Rosser EC, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011;186:5569–5579.
41. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008;224:201–214.
42. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD51 phenotype controls T cell-dependent inflammatory responses. Immunity 2008;28:639–650.
43. Ding Q, Yeung M, Camirand G, et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest 2011;121:3645–3656.
44. Lee KM, Kim JI, Stott R, et al. Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells. Am J Transpl 2012;12:2072–2078.
45. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997;186: 1749–1756.
46. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006;176:705–710.
47. Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014;507:366–370.
48. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004;172:3422–3427.
49. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naïve human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092–6099.
50. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944–950.
51. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010;67:452–461.
52. Lampropoulou V, Hoehlig K, Roch T, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 2008;180:4763–4773.
53. Rieger A, Bar-Or A. B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nat Rev Immunol 2008;8:486–487.
54. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 2000;12:597–605.
55. Mauri C, Gray D, Mushtag N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489–501.
56. Lenert P, Brummel R, Field EH, Ashman RF. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005;25:29–40.
57. Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN, Fallon PG. Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol 2004;173:6346–6356.
58. Blair PA, Norena LY, Flores-Borja F, et al. CD19(1)CD24 (hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010;32:129–140.
59. Gonnella PA, Waldner HP, Weiner HL. B cell-deficient (mu MT) mice have alterations in the cytokine microenvironment of the gut-associated lymphoid tissue (GALT) and a defect in the low dose mechanism of oral tolerance. J Immunol 2001;166:4456–4464.